Single and Combination Immunotherapy with Chemotherapy and the Risk of AKI in Patients with Solid Cancer

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Nov 23

PMID 37995062

Authors

Germana Alves de Brito

Antonio Paulo Nassar Junior

Milton Barros E Silva

Barbara Beltrame Bettim

Benedito Jorge Pereira

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Acute kidney injury (AKI) has emerged as an important toxicity among patients with advanced cancer treated with immune checkpoint inhibitors. The aim of this study was to describe the incidence, risk factors and mortality of AKI in patients receiving immune checkpoint inhibitors alone or in combination with another form of immunotherapy or chemotherapy.

Design, Setting And Participants: We included all patients who received immune checkpoint inhibitors alone or in combination with another form of immunotherapy or chemotherapy at AC Camargo Cancer Center from January 2015 to December 2019. AKI was defined as a ≥ 1.5 fold increase in creatinine from baseline within 12 months of immune checkpoint inhibitor initiation. We assessed the association between baseline demographics, comorbidities, medications and risk of AKI using a competing risk model, considering death as a competing event.

Results: We included 614 patients in the analysis. The mean age was 58.4 ± 13.5 years, and the mean baseline creatinine was 0.8 ± 0.18 mg/dL. AKI occurred in 144 (23.5%) of the patients. The most frequent AKI etiologies were multifactorial (10.1%), hemodynamic (8.8%) and possibly immunotherapy-related (3.6%). The likelihood of AKI was greater in patients with genitourinary cancer (sHR 2.47 95% CI 1.34-4.55 p < 0.01), with a prior AKI history (sHR 2.1 95% CI 1.30-3.39 p < 0.01) and taking antibiotics (sHR 2.85 95% CI 1.54-5.27 p < 0.01).

Conclusions: In this study, genitourinary cancer, previous AKI and antibiotics use were associated with a higher likelihood of developing AKI.

References

Christiansen C, Johansen M, Langeberg W, Fryzek J, Sorensen H . Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011; 22(4):399-406. DOI: 10.1016/j.ejim.2011.05.005. View

Kitchlu A, McArthur E, Amir E, Booth C, Sutradhar R, Majeed H . Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. J Natl Cancer Inst. 2018; 111(7):727-736. PMC: 6624169. DOI: 10.1093/jnci/djy167. View

Kemlin D, Biard L, Kerhuel L, Zafrani L, Venot M, Teixeira L . Acute kidney injury in critically ill patients with solid tumours. Nephrol Dial Transplant. 2018; 33(11):1997-2005. DOI: 10.1093/ndt/gfy051. View

Benoit D, Hoste E . Acute kidney injury in critically ill patients with cancer. Crit Care Clin. 2009; 26(1):151-79. DOI: 10.1016/j.ccc.2009.09.002. View

Lahoti A, Kantarjian H, Salahudeen A, Ravandi F, Cortes J, Faderl S . Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010; 116(17):4063-8. PMC: 4181579. DOI: 10.1002/cncr.25306. View

Gupta S, Gudsoorkar P, Jhaveri K . Acute Kidney Injury in Critically Ill Patients with Cancer. Clin J Am Soc Nephrol. 2022; 17(9):1385-1398. PMC: 9625110. DOI: 10.2215/CJN.15681221. View

Rosner M, Jhaveri K, McMahon B, Perazella M . Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin. 2020; 71(1):47-77. DOI: 10.3322/caac.21636. View

Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D . Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013; 8(2):e55870. PMC: 3573047. DOI: 10.1371/journal.pone.0055870. View

Perazella M, Shirali A . Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. Kidney Int. 2019; 97(1):62-74. DOI: 10.1016/j.kint.2019.07.022. View

10.

Koks M, Ocak G, Suelmann B, Hulsbergen-Veelken C, Haitjema S, Vianen M . Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. PLoS One. 2021; 16(6):e0252978. PMC: 8186792. DOI: 10.1371/journal.pone.0252978. View

11.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

12.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

13.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Leach D, Krummel M, Allison J . Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256):1734-6. DOI: 10.1126/science.271.5256.1734. View

16.

Boussiotis V . Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016; 375(18):1767-1778. PMC: 5575761. DOI: 10.1056/NEJMra1514296. View

17.

Belliere J, Mazieres J, Meyer N, Chebane L, Despas F . Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel). 2021; 11(7). PMC: 8303282. DOI: 10.3390/diagnostics11071187. View

18.

Cortazar F, Marrone K, Troxell M, Ralto K, Hoenig M, Brahmer J . Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016; 90(3):638-47. PMC: 4983464. DOI: 10.1016/j.kint.2016.04.008. View

19.

Weber J, Dummer R, de Pril V, Lebbe C, Hodi F . Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013; 119(9):1675-82. DOI: 10.1002/cncr.27969. View

20.

Seethapathy H, Zhao S, Chute D, Zubiri L, Oppong Y, Strohbehn I . The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019; 14(12):1692-1700. PMC: 6895474. DOI: 10.2215/CJN.00990119. View